Of a test group given both shots, 11 people who'd received bivalent vaccines contracted the virus, while just five people who received the original 'monovalent' shot caught COVID. .
FDA advisor and vaccine maker Paul Offit: “A healthy young person is unlikely to benefit from a booster dose… If there’s not clear evidence of benefit, then it’s not fair to ask people to take a risk.” pic.twitter.com/SgBp5WZbMS.Paul Offit, right, cautions that there are still risks for healthy young people that should be considered before getting the COVID booster shot.
'A healthy young person is unlikely to benefit from the extra dose,' he said.'When you are asking people to get a vaccine, I think there has to be clear evidence of benefit,' he said, adding that it's unrealistic to have clinical trials of the latest dose. 'You'd like to have, at least, human data,' he said'If there's not clear evidence of benefit, then it's not fair, I think, to ask people to take a risk no matter how small,' Offit saidHe said the studies regarding the bivalent vaccine so far were 'underwhelming.'